Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension

References

• Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004;43: 25S–32.
   PubMed Web of Science ®Google Scholar
• Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111–7.
   PubMed Web of Science ®Google Scholar
• Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiéry J-L, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34: 1219–63.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54: S43–54.
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012;142:448–56.
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Yaïci A, Montani D, O’Callaghan DS, Jaïs X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36:549–55.
   PubMed Web of Science ®Google Scholar
• Hesselstrand R, Wildt M, Ekmehag B, Wuttge DM, Scheja A. Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. Scand J Rheumatol. 2011;40:127–32.
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343–9.
   PubMed Web of Science ®Google Scholar
• Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30:394–403.
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al. Macitentan and Morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–18.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330–40.
   PubMed Web of Science ®Google Scholar
• Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76–81.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–11.
   PubMed Web of Science ®Google Scholar
• Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39:589–96.
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353–9.
   PubMed Web of Science ®Google Scholar
• Kemp K, Savale L, O’Callaghan DS, Jaïs X, Montani D, Humbert M, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant. 2012;31:150–8.
   PubMed Web of Science ®Google Scholar
• ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–7.
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119–23.
   PubMed Web of Science ®Google Scholar
• Galiè N, Rubin LJ, Hoeper MM, Jansa P, Al-Hiti H, Meyer GMB, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY-study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093–100.
   PubMed Web of Science ®Google Scholar
• Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch DB, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–57.
   PubMed Web of Science ®Google Scholar
• Actelion. Actelion provides an update on the bosentan study - COMPASS-2 [Internet]. Available from: http://www.actelion.com/en/our-company/news-and-events/index.page?newsId = 1769001 [updated March 17 2014; cited 2014 April 17].
   Google Scholar
• Venitz J, Zack J, Gillies H, Allard M, Regnault J, Dufton C. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012;52:1784–805.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. AMBITION: A randomized, multicenter study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH) [Internet]. 2010- [updated April 15 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01178073.
   Google Scholar
• Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156–63.
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122: 164–72.
   PubMed Web of Science ®Google Scholar
• Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon MD. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest. 2011;139: 1285–93.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780–8.
   PubMed Web of Science ®Google Scholar
• Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27:589–95.
   PubMed Web of Science ®Google Scholar
• Savarese G, Paolillo S, Costanzo P, D’Amore C, Cecere M, Losco T, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012;60:1192–201.
   PubMed Web of Science ®Google Scholar
• Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation. 2012;126:349–56.
   PubMed Web of Science ®Google Scholar
• Fritz JS, Blair C, Oudiz RJ, Dufton C, Olschewski H, Despain D, et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest. 2013;143:315–23.
   PubMed Web of Science ®Google Scholar
• Galiè N, Channick RN, Delcroix M, Ghofrani HA, Jansa P, Le Brun F-O, et al. Sustained effect of macitentan, a novel oral endothelin receptor antagonist, on exercise capacity and the association of its measure with long-term outcomes in pulmonary arterial hypertension. Eur Heart J. 2013;34(Abstract supplement):186.
   Google Scholar
• Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010;35:1079–87.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477–82.
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Ali O, Bradlow W, Wharton J, Taegtmeyer A, Rhodes CJ, et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med. 2010;181:1106–13.
   PubMed Web of Science ®Google Scholar